Getting Worse Not Better: UK Report On Access To Cancer Drugs
A UK report on patient access to cancer drugs suggests that the European Medicines Agency could learn from the US Food and Drug Administration and best practice elsewhere in the world when it comes to taking a faster, more flexible approach to assessing evidence.
You may also be interested in...
NICE, the health technology appraisal body for England and Wales, has rejected criticism that access to cancer drugs is worsening in the UK. The institute pointed to the revamped Cancer Drugs Fund which it said meant more positive recommendations.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).